Bisacodyl Limits Chikungunya Virus Replication <i>In Vitro</i> and Is Broadly Antiviral-Reference-Cited by-同舟云学术

Bisacodyl Limits Chikungunya Virus Replication In Vitro and Is Broadly Antiviral

Published:2022-06-21 Issue:6 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

LoMascolo Natalie J.¹²,Cruz-Pulido Yazmin E.¹,Mounce Bryan C.¹²^ORCID

Affiliation:

1. Department of Microbiology and Immunology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA

2. Infectious Diseases and Immunology Research Institute, Maywood, Illinois, USA

Abstract

Identifying novel antivirals requires significant time and resource investment, and the continuous threat of viruses to human health necessitates commitment to antiviral identification and development. Developing antivirals requires years of research and validation, and recent outbreaks have highlighted the need for preparedness in counteracting pandemics.

Funder

HHS | NIH | National Institute of General Medical Sciences

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00292-22

Reference45 articles.

1. Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections

2. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review

3. Repurposing old molecules for new indications: Defining pillars of success from lessons in the past

4. Strategies for drug repurposing against coronavirus targets

5. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system